TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection
Study: NCT02728050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study: NCT01285674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-tympanic Cisplatinum
Description: Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
Study: NCT00369616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT002-NicQb

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CYT002-NicQb
Study: NCT03506815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: Rivaroxaban 10mg po daily x 90 (+/- 3 days)
Study: NCT01598051

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto_ BAY59-7939)
Description: Patients treated with Xarelto under practical manner for SPAF.
Study: NCT01192867

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally QD for 56 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipshychotics (Standard of Care)
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipshychotics (Standard of Care)
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection
Study: NCT01192867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipshychotics (Standard of Care)
Description: Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
Study: NCT02437435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reproductive Technique Gimilio
Description: Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intervention
Description: Patient supine, legs in triple flexion, feet on table. Physical Therapist take contact with his right hand in patient's belly for 5 minutes, without any movement.
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection
Study: NCT01137994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: monoclonal antibody directed to HER2 receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Taxane chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinka alkaloid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinka alkaloid
Study: NCT00557089

Intervention type: DRUG
Group type: OTHER
Intervention: rhDNAse
Description: 2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.

Intervention type: DRUG
Group type: OTHER
Intervention: rhDNAse
Description: 2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
Study: NCT01761331

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
Study: NCT02663323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
Description: MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1795091
Description: GSK1795091 will be available as solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
Study: NCT01842698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasoundguided paravertebral catheter
Study: NCT00751829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + hydrochlorothiazide, if necessary
Description: oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrendipine + hydrochlorothiazide, if necessary
Description: oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
Study: NCT03866005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes Visual Function Study (DiVFuSS) softgels
Description: The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diabetes Visual Function Study (DiVFuSS) softgels
Description: The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ \[patented extract of French maritime pine bark, Pinus pinaster\], grape seed and green tea extracts, curcumin).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: canola oil placebo softgels, 2 per day
Description: Placebo containing canola oil, 2 softgels per day
Study: NCT00616200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: 4 weeks on strictly controlled low carbohydrate diet
Study: NCT00557089

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: 2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
Study: NCT01738451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436 75 mg
Description: Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436 75 mg
Description: Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436 75 mg
Description: Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be administered in Part 2 of the study.
Study: NCT04380961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Participants will receive single dose infusion of sirukumab on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo IV single dose infusion on Day 1.
Study: NCT01357187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scheduled removal of posterior instrumentation with AmnioFix
Study: NCT04380961

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC treatment will be determined by the investigator based on local practice and consists of supportive care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: SOC treatment will be determined by the investigator based on local practice and consists of supportive care.
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3359609
Description: GSK3359609 will be available as solution for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
Study: NCT01354782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days.
Study: NCT00290537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 IV Over 3 Hours On Day 1
Study: NCT01748864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide (EC20)
Study: NCT02304614

Intervention type: OTHER
Intervention: 3D surface imaging using a non portable and portable camera
Description: The participant will have 3D surface imaging taken of their breasts (the face will not be shown)

Intervention type: OTHER
Intervention: Patient reported outcome measure (PROM): BREAST-Q
Description: The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT

Intervention type: OTHER
Intervention: 2D photography
Description: The participant will have standard medical photography of their breasts (the face will not be shown)

Intervention type: OTHER
Intervention: Applanation Tonometry
Description: A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
Study: NCT04126577

Intervention type: BIOLOGICAL
Intervention: blood samples
Description: 4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
Study: NCT01357187

Intervention type: OTHER
Group type: OTHER
Intervention: Scheduled removal of posterior instrumentation without AmnioFix
Study: NCT03374878

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no oral contraceptive and training
Description: 10 weeks of training in a group of oral contraceptive users

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral contraceptive and training
Description: 10 weeks of training in a group of users of oral contraceptives
Study: NCT00381095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02775721

Intervention type: OTHER
Group type: OTHER
Intervention: Nursing Education related to Gastrostomy Tube Care
Description: The research nurse will provide educational intervention at each study visit utilizing the nursing process.

Intervention type: OTHER
Group type: OTHER
Intervention: Nursing Education related to Gastrostomy Tube Care
Description: The research nurse will provide educational intervention at each study visit utilizing the nursing process.

Intervention type: OTHER
Group type: OTHER
Intervention: Nursing Education related to Gastrostomy Tube Care
Description: The research nurse will provide educational intervention at each study visit utilizing the nursing process.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech Therapy Education and Evaluation
Description: Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech Therapy Education and Evaluation
Description: Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech Therapy Education and Evaluation
Description: Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
Study: NCT03447314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
Study: NCT01920568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab 70 mg/mL
Description: Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Description: Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: The placebo will consist of 1.7 mL 0.9% w/v sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SC
Description: The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplement
Description: Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.